“"Scientific advances are opening up new possibilities for innovative gene therapies, and it is important that regulation keeps pace. These proposals will address a gap in the current definition, providing a clearer route to licensing for certain synthetic gene therapies and greater certainty for developers about the regulatory requirements they need to meet. By providing greater certainty for developers, we can help attract investment, strengthen the UK’s position as a leader in life sciences and support the development of potentially life-saving new treatments for patients."
UK Government Modernises Gene Therapy Definitions to Boost Life Sciences
New regulations aim to provide a clearer regulatory pathway for synthetic gene therapies and genome-editing treatments, fostering innovation while ensuring safety.
By The SME Chronicle Newsroom
••2 min read
AI
Generic image of a DNA helix model with synthetic genetic material strands, illuminated by soft laboratory lighting.
The UK government has confirmed plans to modernise the legal definition of gene therapy medicinal products (GTMPs), aiming to regulate certain synthetic gene therapies and genome-editing treatments under the existing advanced therapies framework.
The proposed changes, supported by 83% of respondents in a consultation led by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Department of Health in Northern Ireland, will amend the Human Medicines Regulations 2012. These amendments are designed to accommodate advances in synthetic genetic material and genome-editing technologies.
These updates are expected to provide developers with greater certainty regarding the classification and regulatory requirements for these medicines, thereby supporting innovation within the UK life sciences sector. The existing standards for safety, quality, and efficacy will remain unchanged, and currently licensed medicines will not require reclassification.
The announcement was made at the inaugural DIA-MHRA Global Summit in London on 16–17 November 2026, part of London Life Sciences Week. The summit brought together international regulators, industry leaders, and patient representatives to discuss global collaboration for innovation and faster patient access.
The current definitions of Advanced Therapy Medicinal Products (ATMPs), established in 2007, have been challenged by innovative therapies involving synthetic genetic material and genome editing. The MHRA, in conjunction with the Department of Health in Northern Ireland, conducted a six-week public consultation to update the GTMP definition, seeking views on amendments to modernise the framework and ensure global alignment.
Following the consultation, the MHRA will proceed with legislation to revise the definitions. The new approach will classify Gene Therapy Medicinal Products (GTMPs) based on whether the active substance contains recombinant or synthetic nucleic acid that undergoes transcription or translation, or if the mechanism of action involves sequence-specific genome editing. This ensures modern synthetic platforms and gene editing systems are appropriately captured within the regulatory framework.
Based on information from the official source: Medicines and Healthcare products Regulatory Agency (19/11/2026)



